The Shenqi Shoutai Pill Joint Active Immune Therapy In Ursa Patients With Early Threatening Miscarriage Clinical Research

Objective: Research Shenqi Shoutai Pill, the clinical efficacy and mechanism ofactive immunotherapy in URSA patients with early threatened abortion and comparedspontaneous abortion and spontaneous abortion≥3times threatened abortion treatment tocontinue the pregnancy success rate is to explore the Chinese and Westernmedicinetocolytic efficacy of combination regimens URSA patients with threatenedabortion.Methods: URSA60cases by the patient abortion times divided into two groups:treatment group1(natural abortion2times) and treatment of two groups (natural abortionquartile3times), each group of each30cases. Observe the scheme in two groups ofpatients with clinical total curative effect, compared to two groups of patients before andafter treatment of traditional Chinese medicine of sickness integral, T lymphocyte subsets(CD3+, CD4+, CD8+and CD4/CD8) change and is pregnant six weeks and nine weeksvaginal B inverted yolk sac diameter and blood beta hCG relevance.Results:1. After treatment, the two groups of patients in the comprehensive effect ofdisease was91.66%, for1group of the total effective rate was93.33%, the total effectiverate of the treatment group2to90%, and comparison between groups not seen significantdifference (P>0.05).2. After treatment, the patient general continue to pregnancy URSAsuccess rate is91.66%, among them for1group of continue to pregnancy success rate of93.33%, the treatment of the two groups continue to pregnancy success rate of90.00%, thetwo groups of patients continue to pregnancy success rate has not seen the differenceobvious (P>0.05).3. Two groups of patients after treatment of traditional Chinese medicinesymptoms have obvious improvement, for1groups before treatment syndrome integral for20.73+/-4.28, after treatment, the syndrome is5.00+/-2.96points;2groups before treatment treatment syndrome integral for21.00+/-6.29, after treatment, the syndrome is6.43+/-3.54points, two groups of symptom scores after treatment than before treatmentwill be improved obviously (P<0.05), and after treatment, the different frequency earlythreatening miscarriage patients syndrome integral is no difference (P>0.05).4. Two groupsof patients before and after treatment T lymphocytes and group of testing, before and aftertreatment were CD4+, CD3+no significant difference (P>0.05), after treatment CD8+rose significantly (P<0.05); CD4/CD8reduce significant difference (P<0.05), and thecomparison between groups not seen significant difference (P>0.05).5.URSA earlythreatening miscarriage patients menopause six weeks and9weeks yolk sac the diameterand blood β-hCG are a positive correlation.Conclusion:1. Shenqi Shoutai Pill joint active immune therapy can improve the jointinitiative URSA patients early threatening miscarriage of pregnancy to continue thesuccess rate.2. Shenqi Shoutai Pill joint active immune therapy in URSA2times of earlythreatening miscarriage patients and URSA3and above the threatening miscarriage ofpatients with early pregnancy no significant difference to continue the success rate.3.Shenqi Shoutai Pill joint active immune therapy can improve the joint initiative Tlymphocyte subsets of the percentage of CD8+cells, reducing the ratio of CD4/CD8.